Latest news with #GuggenheimSecurities
Yahoo
30-07-2025
- Business
- Yahoo
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ('Larimar') (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about July 31, 2025, subject to the satisfaction of customary closing conditions. Leerink Partners, Guggenheim Securities, Truist Securities and William Blair are acting as joint bookrunning managers for the offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses and pre-commercialization expenses. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279275) that was declared effective by the Securities and Exchange Commission ('SEC') on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on July 29, 2025 and is available for free on the SEC's website at A final prospectus supplement with the final terms of the offering and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@ Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@ Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. About Larimar Therapeutics, Inc. Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend,' or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar's management. Such forward-looking statements include, without limitation, statements relating to the completion, use of proceeds and anticipated total gross proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering, and other risks and uncertainties related to the public offering, as well as the risks and uncertainties set forth in the 'Risk Factors' section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at including but not limited to Larimar's periodic reports, including Larimar's most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor Contact:Joyce Allaire LifeSci Advisors jallaire@ (212) 915-2569 Company Contact: Michael CelanoChief Financial Officermcelano@ 414-2715Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
23-07-2025
- Automotive
- Globe and Mail
Tesla Inc: Guggenheim Maintains 'Sell', $175 Target Ahead of Earnings
Tesla Inc. (TSLA) (About (STA Research): Is a Canadian investment research company specializing in advanced stock research and analysis. Our research team comprises of Financial Professionals). Analyst Update Guggenheim Securities has reiterated its 'Sell' rating on Tesla, Inc. and maintained a 12-month price target of $175.00 ahead of the company's upcoming earnings release. The bearish stance reflects concerns over margin pressure, demand uncertainty, and intensifying global EV competition, particularly from Chinese automakers. Guggenheim analysts have previously flagged issues related to Tesla's price cuts across key markets like the U.S., China, and Europe, which may weigh on profitability in the near term. Additionally, investors remains skeptical about Tesla's AI and Full Self-Driving (FSD) monetization timeline and sees limited upside in the core auto business without significant breakthroughs. Maintaining the 'Sell' rating before earnings also signals that Guggenheim anticipates underwhelming quarterly performance or cautious forward guidance from Tesla's management, especially in light of macroeconomic headwinds, slowing global EV sales, and the lack of major new vehicle launches in the current pipeline. Consensus Outlook Tesla currently holds a 'Hold' consensus rating from Wall Street analysts, reflecting a balanced but cautious sentiment. While some analysts remain bullish on Tesla's long-term technological and operational potential, others cite concerns around near-term valuation, profit margins, and competitive pressures. This mixed view is further evidenced by the average 12-month price target of approximately $300, which is below the current trading price—a signal that, in the eyes of analysts, Tesla may be overvalued at current levels.
CNBC
23-07-2025
- Business
- CNBC
This AI-powered software stock could jump another 25%, Guggenheim says
AI-powered Dynatrace is a turnaround story that's building on a strong start to the current fiscal year that ends next March, according to Guggenheim Securities. Analysts led by Howard Ma upgraded shares to buy from neutral and introduced a $66 price target. That implies the stock — down this year but ahead nearly 20% in the past three months — could gain another 25.5% over the next 12 months. Dynatrace, a Boston-based developer of software intelligence platforms, is scheduled to report fiscal first-quarter results on July 30, according to FactSet data. Ma's upgrade is "based on increased confidence that key catalysts for Dynatrace's business are gaining momentum, coupled with a favorable model setup," he said in a Wednesday note to clients. "We believe DT can grow at least mid-teens over the next several years making for a sustainable Rule of 45+ company that stands to benefit from secular tailwinds," Ma said, adding that he expects the company to modestly raise its fiscal year 2026 guidance when it reports results. Dynatrace offers AI-enhanced analytics and automation to help clients monitor and optimize app performance, software development, cyber security practices and other systems infrastructure. DT 1Y mountain Dynatrace performance over the past year. According to Ma, Dynatrace's log management business should power earnings growth well into next year. Improved seasonal trends that began in April could also help drive additional upside, Guggenheim argued, adding that the company is seeing large enterprise customers begin to consolidate more tools on its platform, contributing to subscriptions growth. "Dynatrace's core APM products have been benefiting from continued application modernization, including new app development," Ma said, referring to Application Performance Management. "With a significant percentage of customers now on [Dynatrace Platform Subscription], the collective usage expansion is driving overages and early renewals, which partners say is driving significant deal size uplifts, with some in the 30-50% range (after rate card discounts), and in some cases even doubling."
CNBC
18-07-2025
- Business
- CNBC
Guggenheim's Michael Morris: Drivers of Netlfix earnings beat and raise will continue
Michael Morris, Guggenheim Securities senior managing director, joins CNBC's 'Squawk on the Street' to discuss Netflix's latest earnings report.
Yahoo
13-07-2025
- Business
- Yahoo
Datadog (DDOG) Tumbles 11.4% on Analyst's 'Sell' Reco
Datadog, Inc. (NASDAQ:DDOG) is one of the Datadog fell by 11.4 percent week-on-week as investors unloaded portfolios following a brokerage firm's 'sell' recommendation on its stock. In a market note last week, Guggenheim Securities downgraded Datadog, Inc. (NASDAQ:DDOG) to 'sell' from 'neutral' over fears that its revenues could erode if its largest customer, OpenAI, moves workloads in-house. The brokerage firm underscored OpenAI's ongoing development of its own log management and metric tool, a shift that could dent Datadog, Inc.'s (NASDAQ:DDOG) billings in the second half of the year. Analysts estimate OpenAI to account for around 60 percent of Datadog's AI-native customers, and slash as much as $150 million in revenue hole by 2026. A close-up of a laptop with a software engineer coding on the monitor. For the fourth quarter of the year, Guggenheim Securities expects Datadog, Inc. (NASDAQ:DDOG) to record a 17-percent growth in revenues, much slower than the 24.6-percent gain in the current quarter. Additionally, the brokerage firm expects revenues to grow at a slower pace of 15 percent. While we acknowledge the potential of DDOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
